17 analysts give Bio-Techne stock a USD 68.92 average target

Published on 10/20/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2026 revenue was USD 1.22 billion, with 32.20 percent adjusted margin. Bio-Techne stock costs EUR 64.58 on October 20, 2026 at 7:49 p.m. CEST.

Analyst target and earnings

Seventeen analysts give Bio-Techne an average USD 68.92 target on October 6, 2026.
Fiscal 2026 revenue was USD 1.22 billion and adjusted operating margin was 32.20 percent.
Bio-Techne stock stood at EUR 64.58 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST.

Bio-Techne, US09073M1045, Illustration mit AI erstellt.

Bio-Techne stock has a USD 68.92 average 12-month target from 17 analysts, according to MarketBeat on October 6, 2026. The consensus was Hold, with 15 holds and two buys. The stock stood at EUR 64.58 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST.

Revenue stayed near USD 1.22 billion

Bio-Techne's fiscal 2026 revenue was USD 1.22 billion, compared with USD 1.22 billion in fiscal 2025. The company's investor-relations page identifies the fiscal year as ended June 30, 2026 and lists adjusted operating margin of 32.20 percent and adjusted earnings per share of USD 0.52 for its latest results presentation, according to Bio-Techne.

That combination leaves the analyst view centered on valuation rather than a large sales acceleration. MarketBeat reported quarterly revenue of USD 321.19 million, up 1.30 percent year over year, while quarterly earnings per share of USD 0.52 matched consensus on August 12, 2026.

Stock sits below its yearly high

On the Nasdaq, Bio-Techne traded at USD 72.58 on October 20, 2026 at 1:53 p.m. ET. The quote was USD 0.09 higher than the prior close, with 2,227,478 shares changing hands. Its 52-week range was USD 43.20 to USD 72.69, placing the stock USD 0.11 below the upper boundary.

The Nasdaq quote implied a market capitalization of USD 11.4 billion and a trailing P/E ratio of 62.56. For investors, the gap between the USD 72.58 market price and the USD 68.92 consensus target is the clearest numerical counterweight to the stock's position near its yearly high.

What does the target imply?

Using the Nasdaq price and the MarketBeat target, the stock was 5.04 percent above the consensus target on October 20, 2026. Bio-Techne develops research reagents, analytical instruments and precision diagnostics for research, drug discovery and clinical testing, giving the valuation a direct link to demand for life-science tools.

Price and valuation remain central

The market picture combines a nearly unchanged fiscal-year revenue base with a 32.20 percent adjusted operating margin and a valuation above the analyst average. The next major scheduled reporting date listed for Bio-Techne is November 4, 2026, as shown on the company's investor-relations topic information.

Bio-Techne stock at Lang & Schwarz

Bio-Techne's euro quotation was EUR 64.58 at Lang & Schwarz on October 20, 2026 at 7:49 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Bio-Techne stock.